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Abstract
Background: Urothelial bladder cancer (UBC) is a disease that often is discovered when the tumour is non-muscle
invasive, i.e. in Ta or T1 stage. Some patients will progress into muscle-invasive disease, a potentially deadly condition.
Although there are some prognostic models, the need for prognostic and predictive biomarkers is considerate and
urgent. Membranous expression of podocalyxin-like protein 1 (PODXL) and low expression of the RNA-binding motif 3
(RBM3) has previously been shown to be associated with an aggressive tumour phenotype and poor prognosis in
several forms of cancer, including UBC. In this study, we sought to validate the prognostic impact of PODXL and RBM3
in an independent cohort of UBC.
Methods: Using tissue microarrays and immunohistochemistry, PODXL and RBM3 expression was evaluated in 272
incident UBC cases from the prospective, population-based cohort study Malmö Diet and Cancer. Kaplan-Meier analysis
and Cox proportional hazards modelling were used to evaluate the prognostic impact of these markers on 5-year
overall survival (OS).
Results: In line with previous studies, both membranous PODXL expression and low RBM3 expression was significantly
associated with disadvantageous clinicopathological features. Membranous PODXL expression was significantly
associated with a reduced 5-year overall survival in the entire cohort (univariable HR 3.28; 95% CI 1.89–5.69), but this
association did not remain significant in multivariable analysis. In T1 tumours, PODXL was significantly associated with
reduced survival in univariable analysis (HR = 2.83; 95% CI 1.04–7.72) and borderline significant in multivariable analysis
(HR = 2.60; 95% CI 0.91–7.39). Low RBM3 expression was an independent predictor of a reduced survival in the entire
cohort (univariable HR 3.19; 95% CI 2.02–5.04, and multivariable HR 1.85; 95% CI 1.11–3.09), and in T1 tumours
(univariable HR 2.64; 95% CI 1.11–6.27, and multivariable HR 2.63; 95% CI 1.01–6.84).
Conclusions: A link between membranous PODXL expression and clinically more aggressive tumours was further
confirmed, but PODXL expression was not an independent prognostic biomarker in this study. Low RBM3 expression
was validated as an independent factor of poor prognosis in UBC, including T1 disease. These findings suggest that
these biomarkers could be useful in stratifying patients with non-muscle invasive disease for more aggressive first line
treatment.
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Background
The majority of patients with urothelial bladder cancer
(UBC) have Ta and T1 tumours, i.e. non-muscle invasive
(NMI) disease, at diagnosis [1]. However, the unpredict-
able behaviour of these tumours regarding recurrence
and progression into muscle-invasive disease makes
treatment decisions difficult. NMI lesions are typically
managed with transurethral resection, and selectively
with intravesical therapy [2]. Patients with T1 disease,
particularly those with high-risk features, are at risk of
disease progression and may benefit from additional
therapy. In a recent study of a large cohort of patients
with non-muscle invasive UBC, the progression rates in
T1G3 disease were around 20%, despite local treatment
with Bacillus Calmette Guerin (BCG) [3]. Patients who
progress into muscle-invasive disease (T2–T4) have a
50% risk of developing distant metastasis, even with po-
tentially curative surgery [4]. Moreover, patients with T1
disease that progresses into MI disease seem to have a
worse prognosis than those who present as primary MI
[5, 6]. Surgery via radical cystectomy and pelvic lymph
node dissection, with or without neoadjuvant therapy,
remain the gold standard for potentially curative T2–T4
tumours. The survival rates 5 years after surgery span
between 25 and 80%, being worse with higher pT stage
and the presence of lymph node metastasis [4].
Hence, there is a vast and urgent need to find predict-
ive biomarkers to help clinicians identify the patients
with non-invasive tumours in need of more aggressive
first line treatment, since accurate prediction of the risk
of progression into muscle-invasive disease could be the
key to improving patient survival in the non-muscle in-
vasive tumour group.
Podocalyxin-like protein 1 (PODXL) is a protein in-
volved in cell adhesion and morphology [7, 8]. Strong, in
particular membranous, expression has been found to cor-
relate with more aggressive tumours and poor survival in
many cancer forms such as breast cancer [9], colorectal
cancer [10–12], ovarian cancer [13], glioblastoma [14] as
well as UBC [15]. In the latter study, we showed that
PODXL is an independent risk factor for progressive dis-
ease and death in patients with all T-stages of UBC, as
well as in the Ta/T1 subgroup.
RNA-binding motif protein 3 (RBM3) is an RNA and
DNA binding protein that has previously been shown to
be upregulated in cancer tissues compared with normal
tissue [16], but to be associated with favourable progno-
sis in several major cancer forms such as breast, ovarian,
prostate, testicular, esophageal, colorectal cancer and
malignant melanoma [17–25]. In a previous study, we
examined the prognostic value of RBM3 expression in a
large group of patients with UBC (n = 343), and found
reduced expression to be associated with clinically more
aggressive tumours and an independent factor of poor
prognosis in the cohort as a whole, as well as in the Ta/
T1 group [26].
The aim of this study was to validate the clinicopatho-
logical correlates and prognostic impact of PODXL and




The study encompasses tumours from incident cases of
UBC in the Malmö Diet and Cancer study (MDCS). The
MDCS is a prospective population-based study, primarily
aimed at examining the impact of a Western diet, low in
fruit and vegetables and high in fat, on the risk of certain
types of cancer. The baseline examinations took place be-
tween 1991 and 1996 in Malmö, Sweden. The source popu-
lation invited to participate was comprised by women born
between 1923 and 1950 and men born between 1923 and
1945 (74,138 persons). The cohort and the recruitment
procedures have been published elsewhere [27]. Partici-
pants completed a detailed questionnaire, anthropometric
measurements and a dietary assessment. A total of 28,098
participants completed all baseline examinations. The Eth-
ical Committee at Lund University approved the MDCS. At
the end of follow-up, December 31 2010, a total of 355
cases of incident urothelial cancer (UC) were recorded, of
which 335 (95,7%) were located to the bladder. All cases of
UC were histopathologically re-evaluated by a board certi-
fied pathologist according to the WHO grading system of
2004. The cohort has been described in detail previously
[28] The mean and median follow-up time was 6.25 and
5.04 years, respectively (range 0.11–20.69).
TMA construction and immunohistochemistry
Tissue microarrays (TMAs) were constructed using a
semi-automated arraying device (TMArrayer, Pathology
Devices, Westminster, MD, USA). All tumour samples
were represented in duplicate tissue cores of 1 mm.
Staining of both RBM3 and PODXL was evaluated by
two independent observers (KJ and KB) who were
blinded to clinical and outcome data. Scoring differences
were discussed in order to reach consensus. A total
number of 272 tumours, of which 264 (97.1%) were lo-
cated to the bladder, were eligible for TMA construction.
The cases excluded from TMA-construction had either
only cytology or autopsy specimens available, or an in-
sufficient amount of tumour tissue in the biopsies. A
comparison of the TMA cohort and non-TMA cohort is
provided in [28].
For immunohistochemical analysis, 4-μm TMA sec-
tions were automatically pre-treated using the PT Link
system and then stained in an Autostainer Plus (Dako,
Glostrup, Denmark). For evaluation of PODXL expres-
sion, the antibody AMAb90667, Atlas Antibodies AB,
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Stockholm, Sweden, diluted 1:250, was used. The expres-
sion of PODXL was recorded as negative (0), weak cyto-
plasmic positivity in any proportion of cells (1),
moderate cytoplasmic positivity in any proportion (2),
distinct membranous positivity in ≤50% of cells (3) and
distinct membranous positivity in >50% of cells, as pre-
viously described [10, 11, 15].
For evaluation of RBM3 expression, the mouse mono-
clonal anti-RBM3 antibody AMAb90655, Atlas Anti-
bodies AB, Stockholm, Sweden, diluted 1:150 was used.
RBM3 expression was mainly expressed in the nuclei
and the fraction of cells with nuclear positivity (NF) de-
noted as 0 (0–1%), 1 (2–25%), 2 (26–75%) and 3 (>75%),
and the intensity of the staining ((NI) as 0 (negative), 1
(moderate) and 2 (strong). A combined nuclear score
(NS), e.g. multiplier of NF x NI, was then constructed as
previously described [18, 19, 26].
Statistical methods
Chi-square test was used for comparison of biomarker
expression with patient and tumour characteristics.
Kaplan-Meier analysis and log-rank test were applied to
illustrate differences in survival between different strata
of RBM3 and PODXL expression. Cox regression pro-
portional hazards models were used to estimate the im-
pact of RBM3 and PODXL expression on 5-year overall
survival (OS) in both univariable and multivariable ana-
lysis, adjusted for age at diagnosis (continuous), sex, T-
stage and tumour grade. Classification and regression
tree (CRT) analysis was applied to find an appropriate
cut off value for RBM3 expression.
All calculations were performed using IBM SPSS Sta-
tistics for Mac version 23.0 (IBM, Armonk, NY, USA).
All statistical tests were two-sided and a P-value <0.05
was considered statistically significant.
Results
Distribution of PODXL and RBM3 expression
After antibody staining and optimization, PODXL ex-
pression could be evaluated in 262/264 (99.2%) tumours.
Membranous PODXL staining was denoted in 27/262
cases (10.3%) and there was no obvious heterogeneity
between duplicate cores.
RBM3 expression could be evaluated in 259/264
(98.1%) tumours, whereby negative RBM3 staining (NS
= 0) was denoted in 26 (10.0%) cases, intermediate
staining in 78 (30.1%) cases and strong staining in
>75% of the cells in 155 (59.8%) cases. Interestingly, all
cases with NS 6 or 9, i.e. tumours denoted as being
RBM3 high, were homogenously so. The tumours with
lower expression (NS 0–4) had some heterogeneity
between cores, but remained in the low RBM3 category.
The “worst nuclear score” from each tumour was
chosen for further analysis.
Sample images of the different PODXL and RBM3
stainings are shown in Figs. 1 and 2, respectively.
Associations of PODXL and RBM3 expression with
clinicopathological factors
The associations of PODXL and RBM3 expression, re-
spectively, with patient and tumour characteristics are
shown in Table 1.
Membranous PODXL expression was significantly asso-
ciated with higher T-stage and high-grade tumours (p <
0.001 for both). High RBM3 expression was strongly and
significantly associated with lower T-stage and low-grade
tumours (p = 0.001 for both).
None of the investigated biomarkers were significantly
associated with sex, or age at diagnosis.
Association between PODXL expression and survival
The expression of PODXL was dichotomized into mem-
branous and non-membranous expression in line with
previous studies [11, 15].
As shown in Fig. 3, Kaplan-Meier analysis of the entire
cohort demonstrated a significant association between
membranous PODXL and a shorter 5-year OS in the entire
cohort (p < 0.001, Fig. 3a), and in T1 disease (p < 0.001,
Fig. 3b). PODXL was not prognostic in T2–T4 disease
(Fig. 3c). Notably, no membranous PODXL expression was
seen in Ta tumours.
As shown in Table 2, univariable Cox regression ana-
lysis confirmed the significant association between mem-
branous PODXL expression and a reduced 5-year OS in
the entire cohort (HR 3.28; 95% CI 1.89–5.69) and in T1
tumours (HR 2.83; 95% CI 1.04–7.72). These associa-
tions did however not remain significant in multivariable
analysis (Table 2).
Association between RBM3 expression and survival
Kaplan-Meier analysis of different categories of RBM3
expression (NS) revealed a stepwise reduced 5 year over-
all survival (OS), with the shortest survival for RBM3
negative tumours and the longest survival for the two
highest categories, i.e. NS 6 and 9 (Additional file 1).
CRT analysis confirmed these associations (Additional
file 2). Hence, for statistical purposes, categories of the
expression of RBM3 were dichotomized into low (NS =
0–4), and high (NS = 6–9).
Kaplan Meier analysis revealed that cases with low RBM3
expression had a significantly shorter 5-year OS than cases
with high expression (p < 0.001, Fig. 4a). There was no sig-
nificant association between RBM3 expression and survival
in Ta tumours (data not shown), but in T1 tumours, low
RBM3 expression was significantly associated with a re-
duced 5-year OS (p = 0.023, Fig. 4b). In muscle-invasive
(T2–T4) tumours, there was a borderline significant trend
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towards a reduced 5-year OS for tumours with low RBM3
expression (p = 0.061, Fig. 4c).
As shown in Table 2, univariable Cox regression
analysis confirmed the significant association between
low RBM3 expression and a shorter 5-year OS in the
entire cohort (HR 3.19; 95% CI 2.02–5.02) and in T1
tumours (HR 2.64; 95% CI 1.11–6.27). In multivari-
able analysis, adjusted for age, sex, T-stage and grade,
RBM3 remained an independent prognostic factor in
the entire cohort (HR 1.85; 95% CI 1.11–3.09) and in
T1 tumours (HR 2.63 95% CI 1.01–6.84). In T2–T4
tumours, none of the established clinicopathological
factors remained significant, but RBM3 was borderline
prognostic in both univariable (HR 2.01, 95% CI
0.95–4.23) and multivariable analysis (HR 2.22, 95%
CI 0.94–5.28).
When both PODXL and RBM3 were included in the
multivariable model, only low RBM3 expression and T-
stage remained significant prognostic factors in the en-
tire cohort (HR 1.97; 95% CI 1.18–3.31 and HR 4.88;
95% CI 2.15–11.09, respectively). In the T1 subgroup,
only RBM3 showed a significant association with sur-
vival (HR 2.79; 95% CI 1.05–7.36). In the T2–T4 group,
none of the investigated biomarkers remained signifi-
cant, although RBM3 was borderline so (HR 2.35; 95%
CI 0.97–5.72).
PODXL and RBM3 expression in relation to tumour type
The re-classified tumours were also divided into four
categories according to tumour type, i.e. non-invasive
low grade (n = 98), non-invasive high grade (n = 16),
classic invasive (n = 99) and invasive non-classic (n =
Fig. 1 Sample immunohistochemical images of PODXL staining. Images (40× magnification) representing all different scores from 0 to 4, with 3 and 4
denoting membranous expression in < =50% or > 50% of tumour cells, respectively. Of note, score 2 represents a strong “dot-like” cytoplasming staining
Fig. 2 Sample immunohistochemical images of RBM3 staining. Images (20× magnification) representing different nuclear scores of RBM3 staining,
i.e. fraction × intensity
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51). The non-classic tumour group included UBC
with giant cell carcinoma (n = 2), nested (n = 1), glan-
dular (n = 5), squamous (n = 14), trophoblastic (n = 2),
microcystic (n = 3), micropapillary (n = 9), plasmacy-
toid (n = 1) and sarcomatoid differentiation (n = 11).
Kaplan-Meier analysis demonstrated that the 5-year
OS differed significantly between groups, with the
lowest 5-year OS for the classic group (Additional file
3). This was confirmed in univariable Cox regression
analysis, with the non-classic tumour group having a
significantly reduced survival (HR 8.58, 95% CI 4.87–
15.12, p < 0.001) and this association remained signifi-
cant in multivariable analysis (HR 5.87, 95%CI 1.98–
17.44, p = 0.001). As shown in Table 3, non-classic
tumour types were significantly correlated with a
more advanced higher T-stage (p < 0.001), grade (p <
0.001), membranous PODXL expression (p < 0.001)
and low RBM3 expression (p < 0.001).
After adding tumour type as a factor into the multivar-
iable Cox regression analysis of the entire cohort, to-
gether with both PODXL and RBM3, RBM3 expression
remained significant (HR 1.84, 95% CI 1.09–3.10, p =
0.022), but not PODXL expression (HR 1.43, 95% CI
0.77–2.67, p = 0.257). Addition of tumour type to the
multivariable analyses in Table 2 yielded similar results
(data not shown).
Table 1 Associations between RBM3 and PODXL expression and clinicopathological characteristics
PODXL Expression (n = 262) RBM3 expression (n = 259)
Non-membranous Membranous Low (NS = 0–4) High (NS = 6–9)
N (%) 235 (89.7%) 27 (10.3%) p-value 104 (40.2%) 155 (59.8%) p-value
Age
Mean/median 71.4/71.4 71.2/72.4 0.933 72.2/72.5 70.6/70.5 0.069
Range 51.2–86.6 56.2–86.8 51.3–86.8 51.2–86.6
Sex
Female 67 (84.8%) 12 (15.2%) 0.088 32 (40.0%) 48 (60.0%) 0.973
Male 168 (91.8%) 15 (8.2%) 72 (40.2%) 107 (59.8%)
T-stage
Ta 113 (100.0%) 0 (0.0%) <0.001 30 (26.3%) 84 (73.7%) <0.001
T1 73 (88.0%) 10 (12.0%) 28 (34.6%) 53 (65.4%)
T2–4 49 (74.2%) 17 (25.8%) 46 (71.9%) 18 (28.1%)
Grade
Low 128 (99.2%) 1 (0.8%) <0.001 27 (20.8%) 103 (79.2%) <0.001
High 107 (80.5%) 26 (19.5%) 77 (59.7%) 52 (40.3%)
Fig. 3 Five-year overall survival according to PODXL expression. Kaplan-Meier analysis of PODXL expression in relation to 5-year overall survival in
(a) the full cohort, (b) T1 tumours and (c) T2–T4 tumours
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Table 2 Relative risk of overall death within 5 years according to clinicopathological factors and expression of PODXL and RBM3
n (events) Univariable P-value Multivariable P-value
HR (95% CI) HR (95% CI)
Entire cohort
Agea
Continuous 258 (79) 1.04 (1.01–1.07) 0.010 0.96 (0.59–1.57) 0.875
Sexa
Female 79 (23) 1.00 1.00
Male 179 (56) 1.06 (0.65–1.72) 0.827 1.03 (1.00–1.06) 0.078
Gradea
Low 129 (20) 1.00 1.00
High 129 (59) 3.86 (2.32–6.42) <0.001 1.61 (0.82–3.18) 0.165
Stagea
Ta 113 (16) 1.00 1.00
T1 81 (21) 2.20 (1.14–4.21) 0.018 1.69 (0.81–3.56) 0.165
T2–T4 64 (42) 8.20 (4.58–14.66) <0.001 4.85 (2.23–10.55) <0.001
PODXL expression
Non-membranous 235 (66) 1.00 1.00
Membranous 27 (16) 3.28 (1.89–5.69) <0.001 1.49 (0.83–2.68) 0.181
RBM3 expression
High 155 (29) 1.00 1.00
Low 104 (50) 3.19 (2.02–5.04) <0.001 1.85 (1.11–3.09) 0.018
T1 disease
Agea
Continuous 81 (21) 1.01 (0.96–1.07) 0.604 1.08 (1.00–1.17) 0.066
Sexa
Female 21 (6) 1.00 1.00
Male 60 (15) 1.05 (0.41–2.72) 0.914 0.93 (0.36–2.42) 0.884
Gradea
Low 28 (4) 1.00 1.00
High 53 (17) 2.17 (0.73–6.47) 0.163 1.63 (0.50–6.84) 0.412
PODXL expression
Non-membranous 73 (18) 1.00 1.00
Membranous 10 (5) 2.83 (1.04–7.72) 0.042 2.60 (0.91–7.39) 0.073
RBM3 expression
High 53 (9) 1.00 1.00
Low 28 (12) 2.64 (1.11–6.27) 0.028 2.63 (1.01–6.84) 0.047
T2–T4 disease
Agea
Continuous 64 (42) 1.00 (0.96–1.04) 0.935 1.08 (1.00–1.17) 0.066
Sexa
Female 18 (12) 1.00 1.00
Male 46 (30) 0.77 (0.39–1.52) 0.453 0.93 (0.36–2.42) 0.884
Gradea
Low 4 (2) 1.00 1.00
High 60 (40) 1.79 (0.43–7.44) 0.424 1.63 (0.51–5.25) 0.412
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Discussion
This study examined the prognostic impact of PODXL and
RBM3 expression in tumours from incident cases of UBC
in a large, population-based cohort. The results provide fur-
ther evidence of low RBM3 expression being associated
with unfavourable clinicopathological characteristics and an
independent factor of decreased survival, and of PODXL
expression being associated with more aggressive tumour
characteristics and reduced survival, however not inde-
pendently of established prognostic factors.
PODXL is a protein that in experimental studies is asso-
ciated with epithelial mesenchymal transition (EMT) and,
hence, the invasion and spread of tumours [29]. High ex-
pression of PODXL, in particular in the membrane of
tumour cells, has previously been demonstrated to correl-
ate to an impaired prognosis in many major cancer forms
like breast cancer [9], colorectal cancer [10–12], ovarian
cancer [13], glioblastoma [14] and urothelial bladder can-
cer [15]. The results from this study further validate that
membranous expression of PODXL is correlated to more
aggressive tumours as it could not be demonstrated in
non-invasive Ta-tumours. In addition, it was significantly
associated with a reduced survival in univariable analysis,
in the full cohort and in T1 disease, but not in T2–T4 dis-
ease. The latter may perhaps reflect the fact that more ag-
gressive and unstable tumours reside in the MI group,
therefore diluting the prognostic impact of PODXL ex-
pression in the NMI group. Although this study failed to
demonstrate a significant association between PODXL ex-
pression and survival in multivariable analysis, it should
be pointed out that, apart from T-stage, that was an inde-
pendent prognostic factor in the entire cohort, no other
factors provided an independent prognostic value.
PODXL expression was borderline significantly associated
with a reduced survival in multivariable analysis in the T1
group, which is in line with previous findings [15]. Hence,
the prognostic value of PODXL appears to be most evi-
dent in T1 disease, and its expression may possibly add
value to current prognostic models.
Herein, a significantly decreased 5-year OS was dem-
onstrated for patients with tumours displaying low ex-
pression of RBM3, which is well in line with previous
findings in UBC [26], as well as breast cancer [17], epi-
thelial ovarian cancer [18, 30], prostate cancer [19, 21],
testicular cancer [25], oesophageal and gastric cancer
[23] and melanoma [24].
Table 2 Relative risk of overall death within 5 years according to clinicopathological factors and expression of PODXL and RBM3
(Continued)
PODXL expression
Non-membranous 47 (31) 1.00 1.00
Membranous 17 (11) 1.16 (0.54–2.31) 0.669 1.08 (0.53–2.20) 0.832
RBM3 expression
High 18 (9) 1.00 1.00
Low 46 (33) 2.01 (0.95–4.23) 0.066 2.22 (0.94–5.28) 0.071
aCases included in the univariable analysis of clinicopathological factors were those that had information on both PODXL and RBM3 expression
Fig. 4 Five-year overall survival according to RBM3 expression. Kaplan-Meier analysis of RBM3 expression in relation to 5-year overall survival in (a)
the full cohort, (b) T1 tumours and (c) T2–T4 tumours
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On a cellular level, RBM3 is normally expressed
when cells are exposed to conditions such as hypoxia
and cell starvation. These conditions are present in
the environment of a malignant tumour [31]. The
role of RBM3 in adverse growth conditions is to in-
crease cell survival by means of hindering the normal
decrease of protein synthesis and promoting cells to
continue through the cell cycle [16, 32]. It has the
making of a powerful oncoprotein, but is linked to
an improved survival. Perhaps this reflects the regu-
latory role of its binding to RNA and modulation of
RNA expression, making cells more genetically stable,
or to the correlation between downregulation of
RBM3 and reduced sensitivity to cisplatin in epithe-
lial ovarian cancer in vitro [18], presumably by pro-
cesses involved in DNA integrity and repair [30]. The
indication that RBM3 may be a predictive marker for
cisplatin response is in line with the observed associ-
ation between low RBM3 expression and treatment
failure in non-seminatous testicular germ cell cancer
[25], in which cisplatin treatment is highly effective.
Cisplatin is frequently used for neoadjuvant treat-
ment in MI and palliative treatment in metastatic
UBC [4]. Therefore, it would be of interest to study
the association of RBM3 with cisplatin sensitivity in
this type of cancer.
The T1 category is a subgroup with an urgent need of
prognostic biomarkers, as they have a non-negligible
risk for progression to muscle-invasive stages [33].
Interestingly, low RBM3 expression was the only
significant independent marker of poor prognosis in
the T1 group. Therefore, RBM3 may be a clinically
useful marker to select patients with high risk of
muscle-invasive disease, and, hence, in need of early
cystectomy.
Non-classical differentiation was associated with low
RBM3 expression, membranous PODXL expression and
an adverse outcome for patients. The tumour types in-
cluded in this group are known to have a poor progno-
sis compared to classic UBC, apart from microcystic
differentiation, for which the clinical relevance is
unknown [34, 35]. The association of non-classical tu-
mours with poor prognosis was validated in our study,
however, these subtypes are rare and, compared to the
prognostic impact of the two herein examined bio-
markers, of limited clinical value to the UBC patient
population as a whole.
The herein used antibody for detection of RBM expres-
sion has been extensively validated [20, 30] and the only
seeming contradiction to our findings regarding the prog-
nostic value of RBM3 expression in UBC is a TMA study
on cystectomy specimens [36]. However, clinical follow-up
was only available for 106 patients out of a total reported
number of 274 cases reported in this study, with a mean
duration of 2 years. The data presented did not meet the
reporting recommendations for tumour marker prognostic
studies (REMARK) criteria [37] regarding neither patient
characterization, the reporting of data, nor the analysis and
presentation. The difference in results between this study
and ours may also be due to the fact that the most evident
prognostic value of RBM3 expression seems to be for the
NMI tumours. In terms of clinical application, this is cer-
tainly beneficial. The treatment of MI tumours is cystec-
tomy if the patient is fit for surgery, but the difficulty in
choosing therapies lies more in the NMI group.
Conclusions
The results from this study validate the prognostic value
of PODXL and RBM3 expression in UBC, with RBM3
being the potentially most clinically useful biomarker for
prognostic stratification of patients with T1 disease.
These findings merit further study and validation also in
a prospective setting.
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Additional file 1: Kaplan-Meier analysis of 5-year overall survival according
to all nuclear scores of RBM3 expression. (JPG 33 kb)
Additional file 2: Specified non-classical tumour types and their relation
to PODXL and RBM3 expression. (DOCX 90 kb)
Additional file 3: Kaplan-Meier analysis of 5-year overall survival according
to tumour type. (JPG 764 kb)
Table 3 Associations between RBM3 and PODXL expression and tumour type
PODXL expression RBM3 expression
Non-membranous Membranous Low (NS = 0–4) High (NS = 6–9)
Tumour type Tumour type
Non-invasive low grade
(n = 97)
97 (100%) 0 (0%) p < 0.001 Non-invasive low grade
(n = 98)
25 (25.5%) 73 (74.5%) p < 0.001
Non-invasive high grade
(n = 16)
16 (100%) 0 (0%) Non-invasive high grade
(n = 16)
5 (31.3%) 11 (68.7%)
Invasive classic UBC
(n = 99)
85 (85.9%) 14 (14.1%) Invasive classic UBC
(n = 99)
41 (42,3%) 54 (57.7%)
Invasive non-classic UBC
(n = 50)
37 (74.0%) 13 (26.0%) Invasive non-classic UBC
(n = 48)
33 (68.8%) 15 (31.2%)
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